Moderna, Inc. (NASDAQ:MRNA – Get Rating) Director Noubar Afeyan sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $130.80, for a total transaction of $1,308,000.00. Following the completion of the sale, the director now owns 2,557,209 shares of the company’s stock, valued at $334,482,937.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Noubar Afeyan also recently made the following trade(s):
- On Friday, May 13th, Noubar Afeyan sold 100,000 shares of Moderna stock. The stock was sold at an average price of $134.47, for a total transaction of $13,447,000.00.
- On Wednesday, May 11th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $130.74, for a total transaction of $1,307,400.00.
MRNA stock traded up $11.86 during mid-day trading on Friday, hitting $147.66. The company had a trading volume of 7,538,648 shares, compared to its average volume of 7,593,198. The firm has a market cap of $58.73 billion, a PE ratio of 4.34, a price-to-earnings-growth ratio of 0.81 and a beta of 1.70. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.77. Moderna, Inc. has a 12 month low of $119.01 and a 12 month high of $497.49. The stock’s fifty day moving average price is $152.21 and its two-hundred day moving average price is $189.49.
MRNA has been the subject of a number of research reports. Barclays reduced their price target on shares of Moderna from $404.00 to $210.00 in a report on Friday, February 25th. Redburn Partners upgraded shares of Moderna from a “sell” rating to a “neutral” rating in a report on Tuesday, February 1st. Piper Sandler reduced their price objective on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. Morgan Stanley lifted their price objective on shares of Moderna from $205.00 to $217.00 and gave the company an “equal weight” rating in a report on Tuesday, April 12th. Finally, SVB Leerink reduced their price objective on shares of Moderna from $81.00 to $80.00 and set an “underperform” rating for the company in a report on Friday, March 25th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $236.62.
A number of hedge funds have recently made changes to their positions in MRNA. Baillie Gifford & Co. increased its stake in shares of Moderna by 8.4% in the fourth quarter. Baillie Gifford & Co. now owns 45,772,079 shares of the company’s stock worth $11,625,193,000 after purchasing an additional 3,554,725 shares in the last quarter. Norges Bank purchased a new position in shares of Moderna in the fourth quarter worth about $773,229,000. Coatue Management LLC increased its stake in shares of Moderna by 61.6% in the first quarter. Coatue Management LLC now owns 6,928,147 shares of the company’s stock worth $1,193,443,000 after purchasing an additional 2,641,144 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Moderna by 108.2% in the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after purchasing an additional 1,984,458 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Moderna by 94.3% in the third quarter. Bank of New York Mellon Corp now owns 2,717,705 shares of the company’s stock worth $1,045,936,000 after purchasing an additional 1,319,143 shares in the last quarter. 61.20% of the stock is currently owned by institutional investors and hedge funds.
Moderna Company Profile (Get Rating)
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.
- Get a free copy of the StockNews.com research report on Moderna (MRNA)
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.